What Пангрол 10000 Treats: Main Uses and Benefits

Пангрол 10000 is applied in situations involving certain distressing symptoms related to physical discomfort and systemic imbalance. Its therapeutic role is to provide supportive relief, contributing to easing the overall symptom load and discomfort.

Pancreatic enzyme replacement therapy (PERT) involves the use of enzymes which can generally improve symptoms related to insufficient natural enzyme production.

Supportive Management for Symptom Manifestations

This medication is commonly used across conditions presenting with episodic or fluctuating manifestations, relevant in situations involving symptomatic discomfort. The primary therapeutic domains include supportive management for symptoms associated with conditions characterized by periods of heightened symptoms and recurrent or episodic manifestations. It is used for managing symptoms that interfere with daily comfort, and generally contributes to easing the overall symptom load associated with maldigestion.

“It is considered relevant within therapeutic areas involving heightened responses, aiming to support patients during difficult episodes by easing distress.”

Easing Disruptive Digestive Symptom Clusters

Пангрол 10000 helps address symptom clusters that may become intense or disruptive, such as groups of symptoms related to physical discomfort and systemic imbalance. It is relevant in contexts marked by increased discomfort or tension, and provides supportive relief when symptoms interfere with routine activities. It is often used when short-term symptomatic assistance is needed.

---

Quick Fact: Relevant for symptoms that interfere with daily functioning

Absolute Contraindications (Must Not Use)

Пангрол 10000 is strictly contraindicated for use in patients with a confirmed hypersensitivity or allergy to the active ingredient, pancreatin, or any protein of porcine (pork) origin. Use is also prohibited during an episode of acute pancreatitis or an acute exacerbation of chronic pancreatic disease, as defined in regulatory labeling.

---

Age and Life-Stage Eligibility

The medication is approved for the treatment of Exocrine Pancreatic Insufficiency (EPI) across the entire age span, including infants, children, adolescents, and adults (including older adults). During pregnancy, use is conditional and should only occur if clearly necessary to maintain adequate nutritional status. Use is permitted while breastfeeding, as no systemic effects on the infant are anticipated.

---

Conditions for Restricted or Conditional Use

A critical restriction applies to the dose administered to pediatric patients, as regulatory bodies mandate a maximum limit (e.g., 10,000 lipase units/kg/day) to mitigate the risk of developing fibrosing colonopathy (colonic strictures). Caution is also advised when prescribing to patients with gout or hyperuricemia. Official labeling indicates that patients with renal impairment or hepatic impairment do not require specific labeled dosage adjustments.

Interactions with other medicines and products

The official regulatory interaction profile for Pancreatin products, such as Пангрол 10000, is highly specific to the gastrointestinal tract, reflecting the non-systemic action of the enzymes. No systemic interactions involving hepatic metabolic (CYP450) or drug transporter pathways are officially documented.

Interaction Scope and Classification

Category	Official Regulatory Status
Contraindicated combinations	None documented due to interaction risk.
Systemic PK interactions	None documented (e.g., CYP enzymes, P-gp).
Exposure-modifying substances	Oral Iron Salts; Folate (Folic Acid).

---

Resulting Interaction Structure

Official statements describe that co-administration can result in reduced systemic exposure of certain oral iron salts by interfering with their absorption in the gastrointestinal lumen. Similarly, high doses of Pancreatin products are documented to reduce the absorption of folate (Folic Acid).

A crucial interaction-related constraint involves the integrity of the micro-pellets. Co-administration with pH-altering agents, such as some antacids, may disrupt the enteric coating. This premature dissolution causes the enzymes to be inactivated by gastric acid, reducing the overall efficacy of Пангрол 10000 itself. Administration timing separation may be required with specific agents to preserve the enteric coating integrity, as stated in regulatory labels.

How Пангрол 10000 works

Enzymatic Action on Dietary Macromolecules

The mechanism is based on the delivery of three core pancreatic enzymes—lipase, protease, and amylase—directly into the lumen of the small intestine. These enzymes function as catalysts to chemically break down complex dietary molecules: lipase hydrolyzes fats, protease cleaves proteins, and amylase digests starches into simpler, absorbable units.

---

Local Support for Nutrient Assimilation

The drug's action is entirely peripheral and strictly localized to the gastrointestinal tract, the anatomical site of primary digestion. The enzymatic activity initiates the hydrolytic cascade, which increases the concentration of simple molecules (fatty acids, amino acids, and monosaccharides) at the intestinal surface. This physiological change promotes the efficiency of nutrient assimilation across the intestinal lining, thereby increasing the systemic supply of energy substrates and structural components.

The administration of Пангрол 10000 follows a precise, food-contingent protocol. The approved route of administration is oral use via gastro-resistant hard capsules. Dosing is highly individualized and determined by the degree of exocrine pancreatic insufficiency, requiring adjustment under medical supervision.

Labeled Dosing and Frequency

The medicine must be taken with or immediately after every main meal and snack. The starting adult dose is typically 20,000 to 40,000 lipase units per main meal. The total daily dose should generally not exceed 15,000 to 20,000 lipase units/kg body weight. Doses for snacks are generally half the dose designated for a full meal.

Administration Integrity

To preserve the enteric coating, which prevents stomach acid degradation, the capsule must be swallowed whole with a sufficient amount of liquid. It is strictly prohibited to crush or chew the micro-pellets. If the whole capsule cannot be swallowed, the contents may be mixed with a small amount of acidic soft food (pH le 4.5) and must be consumed immediately without storing the mixture.

Specific Populations and Scheduling

Dosing for pediatric patients is determined by a physician based on the child's weight and is typically calculated in lipase units per kilogram of body weight per meal. If a dose is missed, it is advised to skip the forgotten dose and take the next scheduled dose with the next meal; double doses are not permitted for compensation. The duration of treatment is not time-limited, reflecting its use as chronic replacement therapy.

Research Evidence / Overview of Studies for Пангрол 10000

---

Evidence for use in Pancreatic Exocrine Insufficiency (PEI) due to Chronic Pancreatitis

Pancreatic Exocrine Insufficiency (PEI) is a condition where the pancreas does not produce enough digestive enzymes, often due to chronic pancreatitis. Пангрол 10000 was studied for its role in managing this condition. Research examined short-term randomized controlled trials (RCTs) and other studies in adults with PEI stemming from chronic pancreatitis. These studies focused on measuring outcomes related to systemic or functional imbalance, such as the body's ability to digest and absorb fat, and monitoring changes in key nutritional markers.

Studies reported measurements of fat absorption capacity and described patterns across individuals receiving the studied product compared to those receiving a placebo. This research provides insight into short-term changes in digestive function under the specific conditions of the trials.

---

Evidence for use in Pancreatic Exocrine Insufficiency (PEI) due to Cystic Fibrosis (CF)

PEI is also a common challenge for individuals with Cystic Fibrosis (CF), affecting both children and adults. Research has explored the use of the studied product in this population through clinical trials and observational data. These studies typically monitored digestive function and growth parameters in pediatric patients, while in adults, outcomes related to daily functioning or activity level and nutritional status were observed in research.

Research describes that the studied product was observed alongside measured changes in nutritional status and outcomes reflecting daily functioning or activity level across different age groups. Data show patterns related to how these outcomes evolved or changed within the defined study intervals.

---

Long-term Studies and Follow-up Duration

Most of the available evidence for pancreatic enzyme products was studied for short to intermediate periods, generally spanning several weeks to a few months. Research explored changes that occur over these defined time intervals, such as measurements of fat absorption. Long-term effects are not fully established because large-scale, decade-long clinical trials are rarely conducted for these types of therapies. Consequently, limited information for long-term outcomes exists regarding the duration of observed functional changes or the comprehensive impact on health status over time.

---

What is Still Uncertain about Пангрол 10000

Evidence quality varies across studies, with some relying on smaller sample sizes or having limited follow-up durations. This means that findings describe group patterns, not personal outcomes, and research does not determine whether an individual will respond similarly. Furthermore, comparative evidence is lacking for all potential dosing strategies or regimens. The long-term impact on overall nutritional status and health is an area where data are still emerging, and certainty remains low for effects that span many years.

Key Studies & References

1. Efficacy and safety of pancreatic enzyme replacement therapy on exocrine pancreatic insufficiency: a meta-analysis
2. Pancreatic Enzymes Clinical Care Guidelines - Cystic Fibrosis Foundation (Used for CF evidence, dosing limits, and pediatric/nutritional outcomes)

Common questions about Пангрол 10000 (FAQ)

---

Q: Is it safe to take Пангрол 10000 if I am on a vegan diet?

According to official regulatory documents, the medicine contains Pancreatin, which is derived from the pancreas of pigs (porcine origin). Because of this, regulatory information specifies that a known hypersensitivity or allergy to porcine protein is a condition where the medicine is considered contraindicated (should not be used).

---

Q: Can I drink alcohol while I am on this treatment?

Official drug labels state there is no known direct interaction between the medicine itself and alcohol. However, chronic pancreatitis, the underlying condition often treated with this medicine, can frequently be worsened by continued heavy alcohol use. The decision regarding alcohol consumption is typically made as part of the management plan for the underlying pancreatic disease.

---

Q: What is the effect of taking this medicine on my blood sugar levels?

Official warnings note that the medicine contains purines, and regulatory labels advise caution for individuals with conditions like gout or hyperuricemia due to a potential increase in blood uric acid levels. Additionally, official adverse reaction reports have included instances of changes in blood sugar, specifically hyperglycemia (high blood sugar) and hypoglycemia (low blood sugar).

---

Q: Can I use this medicine to treat my occasional indigestion?

The medicine is specifically approved and indicated by regulatory bodies for the treatment of Exocrine Pancreatic Insufficiency (EPI), a condition where the body lacks sufficient digestive enzymes. Treating general, occasional indigestion unrelated to diagnosed EPI is not an approved or listed indication for this product.

---

Q: What should I do if my stool remains fatty even after taking the medicine?

Official product information indicates that if signs of malabsorption, such as fatty stools (steatorrhea), persist, the dosage may need to be adjusted. The dose is typically confirmed or modified by a healthcare provider to ensure effectiveness, sometimes involving clinical tests that measure fat absorption.

How to Store and Dispose of Пангрол 10000

The storage and disposal of Пангрол 10000 (Pancreatin) must strictly follow official regulatory requirements to maintain the enzyme product's stability and ensure safety.

---

Storage Conditions

• Temperature Control: Do not store the medicine above 25 C. This temperature constraint is mandatory to protect the integrity of the active ingredient.
• Child Safety: The product must always be kept out of the sight and reach of children.
• Stability: If the bottle has been opened, the medicine must be used within 6 months. Do not use the capsules after the expiration date printed on the packaging.

Disposal Instructions

Official instructions prohibit discarding unused or expired Пангрол 10000 into wastewater or with household waste. To ensure environmentally safe disposal, patients must consult a pharmacist for guidance on local requirements for discarding unused medicinal products.